11 completed, 1 terminated. 10 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 10 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow SAM-531: new trials by email Literature Review of SAM-531 trials Research Report on SAM-531
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers PF-05212365 - Healthy | Phase 1 | Completed | Pfizer | 6 | 2010-11-01 | 2011-04-28 |
| Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered SAM-531 and gemfibrozil - Healthy | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 17 | 2009-09-01 | 2010-08-20 |
| Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg - Alzheimer Disease | Phase 2 | Terminated | Pfizer | 526 | 2009-05-01 | 2013-01-31 |
| Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects SAM-531 - Alzheimer Disease | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 6 | 2009-05-01 | 2009-08-26 |
| Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered SAM-531 - Alzheimer Disease | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 14 | 2008-10-01 | 2010-02-08 |
| Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531 SAM-531, placebo - Alzheimer Disease | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 56 | 2008-08-01 | 2009-07-30 |
| Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects SAM-531, placebo, Donepezil - Healthy, Adult | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 25 | 2007-10-01 | 2008-04-22 |
| Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease SAM-531, placebo - Alzheimer Disease | Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 72 | 2007-06-01 | 2009-09-30 |
| Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 SAM-531 - Alzheimer Disease | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 32 | 2007-05-01 | 2009-07-07 |
| Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects SAM-531 - Alzheimer Disease | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 80 | 2006-09-01 | 2007-12-11 |
| Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects SAM-531 - Alzheimer Disease | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 80 | 2006-05-01 | 2007-12-10 |
| Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males SAM-531 - Alzheimer Disease | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 72 | 2006-05-01 | 2009-08-07 |
Alzheimer Disease (11)
Wyeth is now a wholly owned subsidiary of Pfizer (10) · Pfizer (2)
France (4) · United States (3) · Japan (2) · Netherlands (2) · Argentina (1) · Chile (1) · Colombia (1) · Hong Kong (1) · Mexico (1) · New Zealand (1) · Poland (1) · Romania (1) · Russia (1) · South Africa (1) · South Korea (1)